Search in:

Advanced search

Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 6

Submit an article Journal homepage

373

Views

CrossRef citations to date

Altmetric

Reviews

Health-related quality of life in men with metastatic castration–resistant prostate cancer

Abigail GeeBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Amarnath ChallapalliBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Amit BahlBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UKCorrespondence[email protected]

Pages 941-949 | Published online: 29 Oct 2015

Cite this article
https://doi.org/10.1586/14737167.2015.1107479
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Cancer Statistics Registrations, England (Series MB1) – No. 44, 2013. Office for National statistics; 2013 [cited 2015 Sept 15]. Available from: www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations–england–series-mb1-/index.html.
Google Scholar
Cancer Incidence and Mortality in the United Kingdom, 2008-10. Office for National Statistics; 2012 [cited 2015 Sept 15]. Available from: www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and mortality/index.html.
Google Scholar
Bahl A, Masson S, Birtle A, et al. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev. 2014;40:170–177.
PubMed Web of Science ®Google Scholar
Colloca G, Venturino A, Checcaglini F. Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review. Cancer Treat Rev. 2010;36:501–506.
PubMed Web of Science ®Google Scholar

A systematic review of patients treated with cytotoxic chemotherapy, comparing results by traditional medical and patient-reported outcomes assessment.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
PubMed Web of Science ®Google Scholar
Schmidt S, Garin O, Pardo Y, et al. Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Qual Life Res. 2014;23:2169–2181.
PubMed Web of Science ®Google Scholar
Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928.
PubMed Web of Science ®Google Scholar
Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277–299.
PubMed Web of Science ®Google Scholar
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
PubMed Web of Science ®Google Scholar
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
PubMed Web of Science ®Google Scholar
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.
PubMed Web of Science ®Google Scholar
Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186–1196.
PubMed Web of Science ®Google Scholar
Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
PubMed Web of Science ®Google Scholar
Diels J, Hamberg P, Ford D, et al. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Qual Life Res. 2015;24:591–598.
PubMed Web of Science ®Google Scholar
Osoba D, Tannock IF, Ernst DS, et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654–1663.
PubMed Web of Science ®Google Scholar
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–245.
PubMed Web of Science ®Google Scholar
Horwich A, Parker C, de Reijke T, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi106–vi114.
PubMed Web of Science ®Google Scholar
Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24:2402–2428.
PubMed Web of Science ®Google Scholar
Bahl A, Masson S, Malik Z, et al. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 2015. Epub 2015 Jan 30. DOI:10.1111/bju.13069.
Web of Science ®Google Scholar

Discusses safety and QoL data in the UK expanded access programme.

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.
PubMed Web of Science ®Google Scholar
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
PubMed Web of Science ®Google Scholar
Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;24:1017–1025.
PubMed Web of Science ®Google Scholar
Harland S, Staffurth J, Molina A, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013;49:3648–3657.
PubMed Web of Science ®Google Scholar
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–160.
PubMed Web of Science ®Google Scholar
Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755–1756.
PubMed Web of Science ®Google Scholar
Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16:509–521.
PubMed Web of Science ®Google Scholar

Discusses QoL outcome with Enzalutamide in the pre-chemotherapy setting.

Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol. 2014;11:335–345.
PubMed Web of Science ®Google Scholar
DePuy V, Anstrom KJ, Castel LD, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15:869–876.
PubMed Web of Science ®Google Scholar
Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16:579–584.
PubMed Web of Science ®Google Scholar
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–1468.
PubMed Web of Science ®Google Scholar
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–822.
PubMed Web of Science ®Google Scholar
Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25:1423–1436.
PubMed Web of Science ®Google Scholar
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
PubMed Web of Science ®Google Scholar
Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014;106:dju 132.
Web of Science ®Google Scholar
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159.
PubMed Web of Science ®Google Scholar
Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–3448.
PubMed Web of Science ®Google Scholar

Provides treatment recommendations for patients with MCRPC including a detailed discussion on impact on HRQoL

Bourke L, Boorjian SA, Briganti A, et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol. 2015;68:374–383.
PubMed Web of Science ®Google Scholar
Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. JAMA. 2009;302:741–749.
PubMed Web of Science ®Google Scholar
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–742.
PubMed Web of Science ®Google Scholar
Dellis A, Papatsoris AG. The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2014;14:175–179.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Health-related quality of life in men with metastatic castration–resistant prostate cancer

References

A systematic review of patients treated with cytotoxic chemotherapy, comparing results by traditional medical and patient-reported outcomes assessment.

Discusses safety and QoL data in the UK expanded access programme.

Discusses QoL outcome with Enzalutamide in the pre-chemotherapy setting.

Provides treatment recommendations for patients with MCRPC including a detailed discussion on impact on HRQoL

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Health-related quality of life in men with metastatic castration–resistant prostate cancer

References

A systematic review of patients treated with cytotoxic chemotherapy, comparing results by traditional medical and patient-reported outcomes assessment.

Discusses safety and QoL data in the UK expanded access programme.

Discusses QoL outcome with Enzalutamide in the pre-chemotherapy setting.

Provides treatment recommendations for patients with MCRPC including a detailed discussion on impact on HRQoL

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date